Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Stock Has Consensus Target Price of $11.25 According to Analysts

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $11.25.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th.

Institutional Trading of Evaxion A/S

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rathbones Group PLC purchased a new position in Evaxion A/S during the 1st quarter worth $170,000. Renaissance Technologies LLC acquired a new position in Evaxion A/S in the first quarter valued at $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Evaxion A/S in the first quarter valued at about $112,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Trading Up 4.0%

EVAX opened at $2.86 on Wednesday. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. Evaxion A/S has a 52 week low of $2.67 and a 52 week high of $6.92. The business’s 50 day moving average is $3.14 and its two-hundred day moving average is $3.45. The firm has a market cap of $25.80 million, a price-to-earnings ratio of -2.36 and a beta of 0.60.

Evaxion A/S Company Profile

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to develop novel immunotherapies and vaccines. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease-specific targets and support the development of treatments tailored to individual patients or pathogens. The company’s research and development activities focus primarily on personalized cancer vaccines and vaccines for infectious diseases. Evaxion’s pipeline has included programs intended to stimulate the immune system to recognize and attack cancer cells, as well as vaccine candidates targeting bacterial and viral infections.